Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04650893 · ClinicalTrials.gov registry record · Phase 3
The Effect of IV NSAID's and Corticosteroids on Dysphasia and Dysphonia Following ASDF
A Phase 3 study, sponsored by University of Nebraska.
- Terminated
- Registry status
- Phase 3
- Development phase
- 33
- Enrollment target
NCT04650893: Clinical Trial Phase 3 study, sponsored by University of Nebraska.
NCT04650893 is a Phase 3 study that was terminated before completion, run by University of Nebraska. The registered enrollment target is 33 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04650893, a Phase 3 study, was terminated before completion, sponsored by University of Nebraska.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 33 participants
- Enrollment target
Study Summary
This study is to assess the efficacy of intra-operative intravenous non-steroidal anti-inflammatory drug (Ketorolac) versus intravenous (dexamethasone) administration on dysphagia and dysphonia after anterior cervical discectomy and fusion (ACDF).
Primary Outcome
The Bazaz grading system (0-none; 1-Mild; 2-Moderate; 3-Severe) is used for dysphagia evaluation
Interventions
- DRUG Placebo
- DRUG Intravenous Dexamethasone
- DRUG Intravenous Ketorolac
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2021-01-02 |
| Est. Completion | 2023-12-08 |
| Phase | Phase 3 |
Why NCT04650893 stopped before completion
NCT04650893 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04650893 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04650893 about?
NCT04650893 is a clinical study titled "The Effect of IV NSAID's and Corticosteroids on Dysphasia and Dysphonia Following ASDF". This study is to assess the efficacy of intra-operative intravenous non-steroidal anti-inflammatory drug (Ketorolac) versus intravenous (dexamethasone) administration on dysphagia and dysphonia after anterior cervical discectomy and fusion (ACDF).
What is the current status of trial NCT04650893?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 33 participants. The study started on 2021-01-02. Estimated completion is 2023-12-08.
What interventions are being tested in trial NCT04650893?
The interventions under investigation include: Placebo (DRUG), Intravenous Dexamethasone (DRUG), Intravenous Ketorolac (DRUG).
Who is sponsoring clinical trial NCT04650893?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04650893's enrollment target sits among peer trials
33 1907th of 2000 higher than 92 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI